Eosinophils, beyond IL-5.
Document type :
Article dans une revue scientifique: Éditorial
DOI :
PMID :
Permalink :
Title :
Eosinophils, beyond IL-5.
Author(s) :
Esnault, Stéphane [Auteur]
University of Wisconsin-Madison
University of Wisconsin School of Medicine and Public Health
Johansson, Mats W [Auteur]
University of Wisconsin-Madison
Mathur, Sameer K [Auteur]
University of Wisconsin-Madison
University of Wisconsin-Madison
University of Wisconsin School of Medicine and Public Health
Johansson, Mats W [Auteur]
University of Wisconsin-Madison
Mathur, Sameer K [Auteur]
University of Wisconsin-Madison
Journal title :
Cells
Abbreviated title :
Cells
Volume number :
10
Pages :
2615
Publisher :
MDPI
Publication date :
2021-10-01
ISSN :
2073-4409
English keyword(s) :
Anti-Asthmatic Agents
Antibodies, Monoclonal, Humanized
Asthma
Eosinophils
Humans
Interleukin-5
Antibodies, Monoclonal, Humanized
Asthma
Eosinophils
Humans
Interleukin-5
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
New therapeutic monoclonal antibodies targeting the IL-5/IL-5 receptor pathway are extremely efficient in depleting blood eosinophils from subjects with asthma. In asthma, these anti-IL-5 therapies reduce exacerbations by ...
Show more >New therapeutic monoclonal antibodies targeting the IL-5/IL-5 receptor pathway are extremely efficient in depleting blood eosinophils from subjects with asthma. In asthma, these anti-IL-5 therapies reduce exacerbations by 50% in eosinophilic severe asthma, but they are not available for patients with milder eosinophilic asthma. In addition, it is well known that these therapies do not totally deplete lung eosinophils and do not seem to change their phenotype [1,2]. Eosinophils are produced in IL-5 knock-out mice, and patients receiving neutralizing anti-IL-5 therapies retain a stable population of residual blood eosinophils closely similar to those of healthy individuals [3,4]. In fact, it is uncertain whether the lack of complete depletion of either residual or activated eosinophils is beneficial or detrimental for patients. Despite the advantage of the anti-IL-5 specificity on eosinophils, the redundancy of the three beta chain receptor cytokines (IL-3, IL-5 and GM-CSF) on eosinophils is well known and may explain the lack of complete depletion of eosinophils [5]. However, in mouse, blockade of the common beta chain receptor did not completely deplete the presence of terminally differentiated eosinophils in the blood [6], suggesting that other factors can differentiate and mature eosinophils. Of note, asthma is only one of numerous eosinophilic diseases, and anti-IL-5 therapies have not yet proven their clinical efficacy to treat most of these devastating diseases. In this Special Issue, several original studies and reviews point out the necessity to continue our efforts to better characterize the heterogeneity of precursor and mature eosinophil populations and to provide new insights regarding other therapeutic targets, which would act on the differentiation and activation of general and specific eosinophil populations.....Show less >
Show more >New therapeutic monoclonal antibodies targeting the IL-5/IL-5 receptor pathway are extremely efficient in depleting blood eosinophils from subjects with asthma. In asthma, these anti-IL-5 therapies reduce exacerbations by 50% in eosinophilic severe asthma, but they are not available for patients with milder eosinophilic asthma. In addition, it is well known that these therapies do not totally deplete lung eosinophils and do not seem to change their phenotype [1,2]. Eosinophils are produced in IL-5 knock-out mice, and patients receiving neutralizing anti-IL-5 therapies retain a stable population of residual blood eosinophils closely similar to those of healthy individuals [3,4]. In fact, it is uncertain whether the lack of complete depletion of either residual or activated eosinophils is beneficial or detrimental for patients. Despite the advantage of the anti-IL-5 specificity on eosinophils, the redundancy of the three beta chain receptor cytokines (IL-3, IL-5 and GM-CSF) on eosinophils is well known and may explain the lack of complete depletion of eosinophils [5]. However, in mouse, blockade of the common beta chain receptor did not completely deplete the presence of terminally differentiated eosinophils in the blood [6], suggesting that other factors can differentiate and mature eosinophils. Of note, asthma is only one of numerous eosinophilic diseases, and anti-IL-5 therapies have not yet proven their clinical efficacy to treat most of these devastating diseases. In this Special Issue, several original studies and reviews point out the necessity to continue our efforts to better characterize the heterogeneity of precursor and mature eosinophil populations and to provide new insights regarding other therapeutic targets, which would act on the differentiation and activation of general and specific eosinophil populations.....Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
Université de Lille
Inserm
CHU Lille
Inserm
CHU Lille
Collections :
Submission date :
2023-10-18T11:52:36Z
2023-10-25T08:33:12Z
2023-10-25T08:33:12Z
Files
- Eosinophils, beyond IL-5.pdf
- Version éditeur
- Open access
- Access the document